The All Wales Medicines Strategy Group (AWMSG) has issued a Final Appraisal Recommendation on the use of alteplase (Actilyse® Cathflo® 2 mg) for occluded central venous access devices within NHS Wales.

The Group recommends alteplase as an option for the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis. The Group was also of the opinion that alteplase is not suitable for shared care within NHS Wales.

Further information, including the assessment report, can be accessed via the link below.